<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974272</url>
  </required_header>
  <id_info>
    <org_study_id>PR-015</org_study_id>
    <nct_id>NCT00974272</nct_id>
  </id_info>
  <brief_title>Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation</brief_title>
  <official_title>Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl T. Hayden VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl T. Hayden VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to determine the acute effects of exenatide on postprandial
      hypertriglyceridemia. Secondary goals are to determine whether there are additional
      improvements in postprandial lipids and lipoproteins and whether (by the reduction of
      hyperglycemia alone or in combination with declines in hyperlipidemia) exenatide reduces the
      pro-inflammatory potential of the postprandial period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglyceride concentration in serum</measure>
    <time_frame>Before and up to 8-hours post-injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum or plasma lipoproteins, apolipoproteins and inflammatory markers; endothelial function</measure>
    <time_frame>Before and up to 8 hours post-injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Single subcutaneous injection (10 μg)</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Single subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recently diagnosed type 2 diabetes (within 3 years) on diet or IGT

          -  Fasting triglyceride levels &gt;140 and &lt; 400 mg/dl and values varying less than 35%
             between two screening measurements

          -  Normal liver function tests and white blood cell count

        Exclusion Criteria:

          -  Type 2 Diabetes for &gt; 3 years or HbA1c ≥ 7.5

          -  Known or suspected Type 1 Diabetes

          -  Any diabetes medications in the past 3 weeks, TZD in the prior 3 months or prior
             regular use of insulin

          -  Creatinine &gt; 2.0 mg/dl or other evidence of active kidney disease

          -  Hepatic enzyme elevation &gt; 2x normal

          -  Known Nonalcoholic Fatty Liver Disease

          -  Malabsorption of fat or other nutrients, severe lactose intolerance or other
             significant gastrointestinal or pancreatic problems

          -  Recent history of nausea or vomiting

          -  Acute bacterial or viral illness or evidence of other active infection in the past 4
             weeks

          -  A prior cardiovascular event, stable or unstable angina or other major illness in the
             past 6 months

          -  Current regular use of anti-inflammatory medications or antioxidants, including over
             the counter medications and high dose salicylates (&gt;1 g/day)

          -  Any lipid lowering therapy in the prior 3 weeks other than a statin medication.
             Subjects receiving a statin medication must be on a stable dose for at least 2 months
             prior to participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter D Reaven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix VA Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix VA Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Peter D Reaven, MD</name_title>
    <organization>Carl T. Hayden VA Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

